ArticleInvestigational new drugs2014

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Carolyn D Britten et al.PubMed ↗Publisher ↗

No numbers read from the abstract.